Search | Clinical Trials Finder

Independent directory Public ClinicalTrials.gov records United States

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: insulin, 20 units twice daily Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide, Glargine Insulin; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: Regular Novolin R, Placebo; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 41 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions: Insulin, Placebo (Sterile diluent); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 27
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Frontotemporal Dementia, Behavioral Variant
Interventions: Novolin-R insulin; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 41 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Glaucoma
Interventions: Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hyperglycemia, Diabetes Mellitus
Interventions: Glargine insulin, Lispro insulin, NPH Insulin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Regular Insulin, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 55 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Seattle, Washington